Project Grant R01CA305974
Award Date 5/15/26
Completion Date 4/30/31
Dollars Obligated $645K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a $399,829 Project Grant on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research into novel dendritic cell-based immunotherapy for solid tumors. The project will deliver mechanistic characterization and preclinical development of AB7H3-TLR4 chimeric antigen receptor (CAR) dendritic cells (DCs)—engineered immune cells designed to overcome tumor immune...
- Federal Grant Award Summary The National Cancer Institute awarded Washington University a $399,829 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a completion date of April 30, 2028. This research project targets the enhancement of neoantigen cancer vaccine efficacy by investigating the mechanisms through which Type 1 Regulatory (TR1) CD4 T cells suppress antitumor immune responses. The research deliverables include scientific studies designed to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $2.47 million under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, with completion targeted for July 31, 2029. This grant supports fundamental research investigating the role of wild-type isocitrate dehydrogenase 1 (WT-IDH1) metabolism in reprogramming the tumor microenvironment of glioblastoma. The research encompasses both in vitro and in...
- Federal Grant Award Summary The National Cancer Institute awarded a $399,829 Project Grant to The Washington University (Office of Sponsored Research Services) effective April 1, 2026, through March 31, 2028, under the Cancer Treatment Research program (CFDA 93.395). The project, titled "Rational Design of Next-Generation Engineered T Cells for Enhanced Cancer Immunotherapy," focuses on developing improved chimeric antigen receptor (CAR) T cell therapies by enhancing T cell persistence...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $3.18 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. Awarded on September 24, 2025, with a completion date of August 31, 2029, this research project will generate fundamental knowledge about how NK cells may suppress the efficacy of ICT in tumor treatment. The study will...
- Federal Grant Award Summary The National Cancer Institute awarded a $542,644 Project Grant to The Washington University (Office of Sponsored Research Services) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026, through March 31, 2031. This five-year research initiative focuses on developing radiation-guided antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC) treatment. The research leverages a breakthrough discovery identifying...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $399,829 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop novel research models for investigating sex-based disparities in glioblastoma (GBM). The award, effective July 7, 2025 through June 30, 2027, funds the creation of investigative tools and methodologies to examine how sex chromosomes and sex hormones influence GBM phenotype, proliferation, and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), through its Cancer Research Manpower program (CFDA 93.398), awarded The Washington University a Project Grant of $333,504 effective July 1, 2025, through July 31, 2027. This award funds research investigating the dynamics and function of peritoneal myeloid cells during colorectal cancer (CRC) peritoneal dissemination and the implications for immunotherapy. The research aims to elucidate the unique roles of myeloid...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $355,706 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2025, through May 31, 2030. The award funds fundamental research aimed at understanding the role of RAMS11 (RNA Associated with Metastasis 11), a long noncoding RNA (lncRNA), in non-small cell lung cancer (NSCLC) development and progression. The research addresses a critical knowledge gap in cancer biology...
- Federal Grant Award Summary Northwestern University received a $496,357 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded on April 17, 2026, with a completion date of March 31, 2031. The research focuses on developing improved cancer treatment methods through investigation of glioblastoma (GBM) immunobiology and therapeutic targeting strategies. Specifically, the project examines mechanisms of tumor-associated macrophage...